Landscape Capital Management L.L.C. Acquires Shares of 21,939 Organon & Co. (NYSE:OGN)

Landscape Capital Management L.L.C. bought a new position in Organon & Co. (NYSE:OGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,939 shares of the company’s stock, valued at approximately $420,000.

Several other hedge funds and other institutional investors have also modified their holdings of OGN. LSV Asset Management raised its stake in Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after acquiring an additional 2,121,940 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Organon & Co. by 39.8% during the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after purchasing an additional 988,336 shares in the last quarter. Deprince Race & Zollo Inc. increased its position in shares of Organon & Co. by 6.8% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock worth $70,829,000 after purchasing an additional 216,907 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Organon & Co. by 23.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock valued at $49,843,000 after purchasing an additional 463,216 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its position in Organon & Co. by 3.4% in the second quarter. Thompson Siegel & Walmsley LLC now owns 2,125,922 shares of the company’s stock valued at $44,007,000 after buying an additional 69,843 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Up 2.6 %

OGN opened at $15.28 on Monday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10. The stock has a market capitalization of $3.94 billion, a PE ratio of 3.03, a PEG ratio of 0.70 and a beta of 0.84. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a 50-day moving average price of $17.61 and a two-hundred day moving average price of $19.77.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period last year, the company earned $0.78 earnings per share. Organon & Co.’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.33%. Organon & Co.’s payout ratio is currently 22.22%.

Wall Street Analysts Forecast Growth

OGN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the company from $18.00 to $20.00 in a research note on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.